SecBot SecBot
PRESS-RELEASE ·Filed May 15, 2026

INKT

MiNK Therapeutics
BULLISH
Impact 6/10
Horizonweeks Processed6mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▲ Bullish

The EPS beat and narrowing loss are positive for a micro-cap biotech, but the $9.5M cash runway (approx. 5-6 quarters at current burn) and reliance on ATM financing introduce dilution risk. Watch for Phase 2 ARDS data in H2 2026 and the ATS presentation on May 20 for near-term catalysts. The non-dilutive collaborations reduce capital burden but are small in absolute size.

DirectionBullish
Confidencemedium
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$10.72
T+0 close · May 15, 2026 · via day close
Latest settled
+4.76%
T+60 · $11.23
Vs SPY
+0.24%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 15 $10.72entry
  2. T+1 · 6mo ago −6.34%α −6.28% · $10.04
  3. T+5 · 6mo ago +1.40%α +0.44% · $10.87
  4. T+20 · 5mo ago +16.93%α +14.81% · $12.54
  5. T+60 · 3mo ago +4.76%α +0.24% · $11.23

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

MiNK Therapeutics reported Q1 2026 EPS of -$0.57, beating consensus of -$0.77 by 26%, with net loss narrowing to $2.7M from $2.8M YoY. The company initiated a randomized Phase 2 trial for agenT-797 in acute lung injury, secured non-dilutive funding for pipeline expansion, and ended the quarter with $9.5M cash after repaying a $5.2M convertible note. The EPS beat is notable for a clinical-stage biotech, but the cash burn and early-stage pipeline keep the impact moderate.

Key Financial Metrics

EPS
−$0.57
est −$0.77 · +26.0%
Rating
beat

Key Facts

  • Q1 2026 EPS -$0.57 vs consensus -$0.77 (26% beat)
  • Net loss $2.7M vs $2.8M YoY; net loss per share improved from -$0.70 to -$0.57
  • Cash and equivalents $9.5M as of March 31, 2026, down from $13.4M at year-end 2025
  • Repaid $5.2M Agenus convertible note; raised $3.0M via ATM during Q1
  • Initiated randomized Phase 2 trial for agenT-797 in severe acute lung injury/ARDS; preliminary data expected H2 2026
  • Non-dilutive collaboration with C-Further provides up to $1.1M for PRAME-targeted iNKT therapy in pediatric cancers
  • AACR/ASGCT data showed 77% disease control rate in PD-1 refractory gastroesophageal cancer; median PFS 6.9 months with immune induction vs 3.5 months without
  • Upcoming ATS presentation on agenT-797 + N-803 for persistent Coccidioides infection on May 20, 2026

Financial Impact

EPS beat of 26% on a -$0.77 consensus; net loss improved $0.1M YoY; cash burn $1.7M in operations during Q1

epsnet losscash positiondilution from ATM

Risk Factors

  • Cash runway limited to ~5-6 quarters at current burn rate; may require additional financing
  • Phase 2 ARDS trial is early-stage with binary outcome risk; no approved pharmacologic therapies exist for ARDS
  • ATM program dilutes existing shareholders; $3.0M raised in Q1
  • Stock is micro-cap ($52M market cap) with low liquidity and high volatility

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
88% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3295757

Track record

21 reports on INKT

Performance horizon

4 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +14.37% at T+20 after the May 14, 2026 report. 4 of 6 went positive at some point.

Filters
  1. Nov 12, 20264d ago 8-K Neutral 4/10 Entry $9.53 Now $9.35 −1.89% settles Dec 11
  2. Nov 11, 20265d ago Press Release Neutral 4/10 Entry $10.22 Now $9.35 −8.55% settles Dec 10
  3. Nov 2, 202614d ago Press Release Neutral 2/10 Entry $10.79 Now $9.35 −13.35% settles Dec 2
  4. Oct 13, 20264w ago 144 Neutral 2/10 Entry $10.23 to $10.01 Now $9.35 −8.60% ▼ −2.15% +1.46% vs SPY
  5. Oct 2, 20266w ago Press Release Neutral 4/10 Entry $12.44 to $10.53 Now $9.35 −24.84% ▼ −15.35% −13.55% vs SPY
  6. Aug 13, 202613w ago 8-K Mixed 6/10 No price data
  7. Aug 13, 202613w ago Press Release Mixed 6/10 Entry $11.00 to $12.00 Now $9.35 −15.00% ▲ +9.09% +10.84% vs SPY
  8. Aug 6, 202614w ago Press Release Bullish 6/10 Entry $11.00 to $11.23 Now $9.35 −15.00% ▲ +2.09% +1.49% vs SPY
  9. May 28, 202624w ago Press Release Neutral 4/10 Entry $12.20 to $11.64 Now $9.35 −23.36% ▼ −4.59% −1.45% vs SPY
  10. May 20, 202625w ago Press Release Neutral 4/10 Entry $10.72 to $12.14 Now $9.35 −12.78% ▲ +13.25% +12.51% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens Wed (10h 5m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 15, 2026